Cardiovascular properties of the kallikrein-kinin system

被引:30
作者
Sharma, JN
Sharma, J
机构
[1] Kuwait Univ, Fac Pharm, Hlth Sci Ctr, Dept Appl Therapeut, Safat 13110, Kuwait
[2] Mem Univ Newfoundland, Sch Nursing, Hlth Sci Ctr, St John, NF A1B 3V6, Canada
关键词
kallikrein-kinin system; bradykinin; bradykinin antagonists; hypertension; cardiac diseases;
D O I
10.1185/03007990212500093
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
All the components of the kallikrein-kinin system are located in the vascular smooth muscle as well as in the heart. In recent years, numerous observations obtained from clinical and experimental models of diabetes, hypertension, cardiac failure, ischaemia, myocardial infarction and left ventricular hypertrophy, have suggested that the reduced activity of the local kallikrem-kinin system may be instrumental in the induction of cardiovascular-related diseases. The ability of kallikrein gene delivery to produce a wide spectrum of beneficial effects makes it an excellent candidate in treating hypertension, and cardiovascular and renal diseases. In addition, stable kinin agonists may also be available in the future as therapeutic agents for cardiovascular and renal disorders.
引用
收藏
页码:10 / 17
页数:8
相关论文
共 100 条
[1]   The effect of bradykinin and its antagonist on survival time after coronary artery occlusion in hypertensive rats [J].
Abbas, SA ;
Sharma, JN ;
Yusof, APM .
IMMUNOPHARMACOLOGY, 1999, 44 (1-2) :93-98
[2]   Effect of bradykinin and its antagonist on survival time after coronary artery occlusion in rats [J].
Abbas, SA ;
Sharma, JN ;
Pauzi, A ;
Yusof, M .
GENERAL PHARMACOLOGY-THE VASCULAR SYSTEM, 1999, 33 (03) :243-247
[3]  
ADETUYIBI A, 1972, LANCET, V2, P203
[4]  
Akbar A, 1998, INT J TISSUE REACT, V20, P95
[5]   MALIGNANT HYPERTENSION - A SYNDROME ASSOCIATED WITH LOW PLASMA KININOGEN AND KININ POTENTIATING FACTOR [J].
ALMEIDA, FA ;
STELLA, RCR ;
VOOS, A ;
AJZEN, H ;
RIBEIRO, AB .
HYPERTENSION, 1981, 3 (06) :46-49
[6]   ANGIOTENSIN CONVERTING ENZYME (ACE) INHIBITORS [J].
Antonaccio, MJ .
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 1982, 22 :57-87
[7]  
Barabe J., 1977, CAN J PHYSL PHARM, V96, P920
[8]  
BHOOLA KD, 1992, PHARMACOL REV, V44, P1
[9]   Shattuck lecture - Cardiovascular medicine at the turn of the millennium: Triumphs, concerns, and opportunities [J].
Braunwald, E .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (19) :1360-1369
[10]  
BURCH RM, 1990, J CARDIOVASC PHARM, V15, pS44, DOI 10.1097/00005344-199015061-00009